Health UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada’s Drug Agency (CDA-AMC) for Acute Migraine Treatment August 4, 2026
Health Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma August 3, 2026
Health BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance July 31, 2026
Health MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF July 29, 2026
Search
Health
August 5, 2026
August 4, 2026
August 3, 2026
July 31, 2026
July 30, 2026
July 30, 2026
July 29, 2026
July 29, 2026
July 29, 2026
July 28, 2026
